Company registration number 10984711 (England and Wales)
3CR BIOSCIENCE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
3CR BIOSCIENCE LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
3CR BIOSCIENCE LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
241,562
190,289
Current assets
Stocks
294,934
143,590
Debtors
4
1,005,681
400,964
Investments
5
-
0
105,169
Cash at bank and in hand
1,507,116
1,291,001
2,807,731
1,940,724
Creditors: amounts falling due within one year
6
(476,910)
(184,711)
Net current assets
2,330,821
1,756,013
Total assets less current liabilities
2,572,383
1,946,302
Provisions for liabilities
(60,391)
(47,572)
Net assets
2,511,992
1,898,730
Capital and reserves
Called up share capital
300
300
Fair value reserve
7
-
0
2,140
Profit and loss reserves
2,511,692
1,896,290
Total equity
2,511,992
1,898,730

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

3CR BIOSCIENCE LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 SEPTEMBER 2025
30 September 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 24 June 2026 and are signed on its behalf by:
Mr S R Asquith
Director
Company Registration No. 10984711
3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 3 -
1
Accounting policies
Company information

3CR BIOSCIENCE LIMITED is a private company limited by shares incorporated in England and Wales. The registered office is Unit 10, West Point Business Park, West Road, Harlow, Essex, CM20 2BU.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Revenue

Turnover is measured at the fair value of the consideration received or receivable e, excluding discounts, rebates, value added tax and other sales taxes.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Over the term of the lease
Plant and equipment
20% on cost
Fixtures and fittings
20% on cost
Computers
33% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowances for obsolete and slow moving items.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.9

Current asset investments

Current asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in profit or loss. Transaction costs are expensed to profit or loss as incurred.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
11
10
3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 5 -
3
Tangible fixed assets
Leasehold improvements
Plant and equipment
Fixtures and fittings
Computers
Total
£
£
£
£
£
Cost
At 1 October 2024
146,838
186,701
42,546
41,641
417,726
Additions
7,451
146,240
-
0
17,218
170,909
At 30 September 2025
154,289
332,941
42,546
58,859
588,635
Depreciation and impairment
At 1 October 2024
57,123
123,893
16,990
29,431
227,437
Depreciation charged in the year
58,075
47,097
6,309
8,155
119,636
At 30 September 2025
115,198
170,990
23,299
37,586
347,073
Carrying amount
At 30 September 2025
39,091
161,951
19,247
21,273
241,562
At 30 September 2024
89,715
62,808
25,556
12,210
190,289
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
957,921
347,193
Amounts owed by group undertakings
-
0
10,300
Other debtors
47,760
43,471
1,005,681
400,964
5
Current asset investments
2025
2024
£
£
Other investments
-
0
105,169
3CR BIOSCIENCE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 6 -
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
365,216
26,868
Taxation and social security
104,403
150,888
Other creditors
7,291
6,955
476,910
184,711
7
Fair value reserve
2025
2024
£
£
At the beginning of the year
2,140
(9,136)
Transfer to retained earnings
(2,140)
11,276
At the end of the year
-
0
2,140
2025-09-30 2024-10-01 false false false 24 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Dr J E Holme Mrs N Jain Mr S R Asquith Mr S Jain Miss W Botten Dr S E Holme Mr S R Asquith 2026-06-24 10984711 2024-10-01 2025-09-30 10984711 2025-09-30 10984711 2024-09-30 10984711 core:LeaseholdImprovements 2025-09-30 10984711 core:PlantMachinery 2025-09-30 10984711 core:FurnitureFittings 2025-09-30 10984711 core:ComputerEquipment 2025-09-30 10984711 core:LeaseholdImprovements 2024-09-30 10984711 core:PlantMachinery 2024-09-30 10984711 core:FurnitureFittings 2024-09-30 10984711 core:ComputerEquipment 2024-09-30 10984711 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 10984711 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 10984711 core:CurrentFinancialInstruments 2025-09-30 10984711 core:CurrentFinancialInstruments 2024-09-30 10984711 core:ShareCapital 2025-09-30 10984711 core:ShareCapital 2024-09-30 10984711 core:RevaluationReserve 2025-09-30 10984711 core:RevaluationReserve 2024-09-30 10984711 core:RetainedEarningsAccumulatedLosses 2025-09-30 10984711 core:RetainedEarningsAccumulatedLosses 2024-09-30 10984711 core:RevaluationReserve 2024-09-30 10984711 core:RevaluationReserve 2023-09-30 10984711 bus:Director3 2024-10-01 2025-09-30 10984711 core:LeaseholdImprovements 2024-10-01 2025-09-30 10984711 core:PlantMachinery 2024-10-01 2025-09-30 10984711 core:FurnitureFittings 2024-10-01 2025-09-30 10984711 core:ComputerEquipment 2024-10-01 2025-09-30 10984711 2023-10-01 2024-09-30 10984711 core:LeaseholdImprovements 2024-09-30 10984711 core:PlantMachinery 2024-09-30 10984711 core:FurnitureFittings 2024-09-30 10984711 core:ComputerEquipment 2024-09-30 10984711 2024-09-30 10984711 core:RevaluationReserve 2024-10-01 2025-09-30 10984711 core:RevaluationReserve 2023-10-01 2024-09-30 10984711 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 10984711 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 10984711 bus:FRS102 2024-10-01 2025-09-30 10984711 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 10984711 bus:Director1 2024-10-01 2025-09-30 10984711 bus:Director2 2024-10-01 2025-09-30 10984711 bus:Director4 2024-10-01 2025-09-30 10984711 bus:Director5 2024-10-01 2025-09-30 10984711 bus:Director6 2024-10-01 2025-09-30 10984711 bus:CompanySecretary1 2024-10-01 2025-09-30 10984711 bus:FullAccounts 2024-10-01 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP